Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Maintaining GDMT while lowering potassium in heart failure

10' education - Mar. 27, 2023 - Javed Butler, MD, Ileana L. Piña, MD, and Patrick Rossignol, MD, PhD

Well-designed EHR tools can improve prescribing of MRA in HFrEF

3' education - Mar. 21, 2023 - Amrita Mukhopadhyay, MD

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD

Protective cardiac effects of statin in patients with lymphoma treated with anthracyclines

3' education - Mar. 5, 2023 - Prof. Marielle Scherrer-Crosbie, MD, PhD

Revascularization in cardiac surgery

10' education - Feb. 28, 2023 - Lauren Barron, MD, Navin Kapur, MD, Adam DeVore, MD

Revascularization in high-risk PCI patients

10' education - Feb. 28, 2023 - Navin Kapur, MD, Adam DeVore, MD, Lauren Barron, MD,

Care gap in assessing CAD

10' education - Feb. 16, 2023 - Adam DeVore, MD, Lauren Barron, MD, Navin Kapur, MD

Treating iron deficiency in patients with HFrEF: A review of the recent data for IV iron replacement therapy

10' education - Jan. 5, 2023 - Prof. Javed Butler, MD, Prof. Stefan Anker, MD, PhD, Piotr Ponikowski, MD, PhD, and Robert J. Mentz, MD

Long-term efficacy and safety of intravenous iron in HF

3' education - Nov. 21, 2022 - Paul R. Kalra

Applying GDMT for iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MD

Maximally tolerated or suboptimal therapy? Clinical perspectives on rechallenging RAASi therapy

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD & Prof. Patrick Rossignol, MD, PhD

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD

Optimizing GDMT in HFrEF and management of hyperkalemia

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Why ischemia matters when it comes to iron deficiency in heart failure

10' education - Nov. 17, 2022 - Prof. Marco Metra, MD & Prof. Piotr Ponikowski, MD, PhD

The role of potassium binders in optimal HF management: Discussing the DIAMOND study

10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MD

New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD

Improved outcomes with rapid uptitration of HF medication after acute HF

3' education - Nov. 8, 2022 - Prof. Alexandre Mebazaa, MD, PhD

Head-to-head comparison of two loop diuretics in patients hospitalized with HF

3' education - Nov. 7, 2022 - Robert J. Mentz, MD

Identification and management of patients with HFpEF and diabetes

10' education - Oct. 26, 2022 - Prof. Silvio Inzucchi, MD & Prof. Pardeep Jhund, MD, PhD

HFpEF and diabetes: What are the clinical challenges?

10' education - Oct. 25, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia

10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD

Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure

10' education - Oct. 12, 2022 - Clara Bonanad Lozano, MD, PhD

How potassium binders can enable RAASi therapy in heart failure

10' education - Oct. 11, 2022 - Prof. Mikhail Kosiborod, MD

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Combination therapy with loop diuretic and acetazolamide improves decongestion in acute HF

3' education - Aug. 27, 2022 - Prof. Wilfried Mullens, MD, PhD

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Prediction of life expectancy and life years gained by medication in HFrEF

3' education - Aug. 27, 2022 - Stefan Koudstaal, MD, PhD

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Maintaining GDMT while lowering potassium in heart failure

10' education - Mar. 27, 2023 - Javed Butler, MD, Ileana L. Piña, MD, and Patrick Rossignol, MD, PhD
Javed Butler, Ileana Piña, and Patrick Rossignol talk about strategies for maintaining optimal GDMT while lowering potassium in patients with HF and hyperkalemia.

Javed Butler, Ileana Piña, and Patrick Rossignol talk about strategies for maintaining optimal GDMT while lowering potassium in patients with HF and hyperkalemia.

Well-designed EHR tools can improve prescribing of MRA in HFrEF

3' education - Mar. 21, 2023 - Amrita Mukhopadhyay, MD
Amrita Mukhopadhyay discusses the BETTER CARE-HF study, which investigated whether an alert or an inbox message delivered via EHR systems to cardiologists, improves prescribing of MRA in patients with HFrEF compared to usual care.

ACC.23 Amrita Mukhopadhyay discusses the BETTER CARE-HF study, which investigated whether an alert or an inbox message delivered via EHR systems to cardiologists, improves prescribing of MRA in patients with HFrEF compared to usual care.

Treatment effects of ARNI in HF independent of eGFR decline during run-in phase

Literature - Mar. 20, 2023 - Chatur S, Claggett BL, McCausland FR, et al. - J Am Coll Cardiol. 2023

Patients with HF may experience a transient decline in eGFR of up to 15-20% after initiation of sacubitril/valsartan. But how does this affect treatment effects? This post hoc analysis of the PARADIGM-HF and PARAGON-HF study offers more insight.

SGLT2i improves CV outcomes in patients with HFmrEF or HFpEF regardless of kidney function

Literature - Mar. 14, 2023 - Mc Causland FR, et al. - JAMA Cardiol. 2023

In this prespecified analysis of the DELIVER trial, the authors evaluated whether baseline kidney function modified the effect of the SGLT2i dapagliflozin on CV improvement in patients with HFmrEF or HFpEF, and determined the effect of dapagliflozin treatment on kidney outcomes.

SGLT2i improves hemodynamic function in HFpEF

News - Mar. 8, 2023

ACC.23 Dapagliflozin reduced pulmonary capillary wedge pressure at rest and during exercise and body weight, amongst others, in HFpEF patients compared with placebo, as shown by the CAMEO-DAPA trial.

Rate-adaptive atrial pacing does not improve exercise performance in HFpEF

News - Mar. 7, 2023

ACC.23 In 29 HFpEF patients with chronotropic incompetence, rate-adaptive atrial pacing did not improve exercise performance or health status. In addition, pacemaker implantation was associated with more adverse events.

Early eGFR decline after transitioning to ARNI not associated with adverse outcomes

3' education - Mar. 6, 2023 - Safia Chatur, MD

ACC.23 "Early treatment-related eGFR decline should not stall uptitration or impede continuation of ARNI", says Safia Chatur. She lists the findings of an analysis of PARADIGM-HF and PARAGON-HF in patients with HF.

EHR alert increases likelihood of prescribing MRA in patients with HFrEF

News - Mar. 6, 2023

ACC.23 An EHR-embedded and selective alert delivered during the clinical encounter increased the likelihood of prescribing MRA by 2.5x in MRA-eligible HFrEF patients in an outpatient cardiology setting.

Myocardial viability assessment does not allow selection of patients who will benefit from PCI

News - Mar. 6, 2023

ACC.23 The REVIVED analyses showed that PCI did not improve prognosis or LV recovery in patients with extensive CAD compared with optimal medical therapy alone, regardless of viability characteristics at baseline.

Protective cardiac effects of statin in patients with lymphoma treated with anthracyclines

3' education - Mar. 5, 2023 - Prof. Marielle Scherrer-Crosbie, MD, PhD
Treatment with anthracyclines may lead to cardiotoxicity. The STOP-CA trial investigated the effect of statin compared with placebo on cardiac dysfunction in patients with lymphoma treated with anthracyclines.

ACC.23 Treatment with anthracyclines may lead to cardiotoxicity. The STOP-CA trial investigated the effect of statins compared to placebo on cardiac dysfunction in patients with lymphoma treated with anthracyclines.

Revascularization in cardiac surgery

10' education - Feb. 28, 2023 - Lauren Barron, MD, Navin Kapur, MD, Adam DeVore, MD

"You can't discount the possibility of revascularization via PCI or surgery in a patient with ischemic cardiomyopathy regardless of what their starting point is", says Lauren Barron. Together with Navin Kapur and Adam DeVore, she discusses revascularization in high-risk surgical patients.

Revascularization in high-risk PCI patients

10' education - Feb. 28, 2023 - Navin Kapur, MD, Adam DeVore, MD, Lauren Barron, MD,
Navin Kapur, Adam DeVore and Lauren Barron discuss the use of mechanical circulatory support for revascularization in high-risk or complex PCI in patients with heart failure and multivessel disease.

Navin Kapur, Adam DeVore and Lauren Barron discuss the use of mechanical circulatory support for revascularization in high-risk or complex PCI in patients with heart failure and multivessel disease.